Vicore Pharma AB (VCRE) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $253.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VCRE | ZNTL |
|---|---|---|
| Share price | $9.00 | $2.64 |
| Market cap | $253.48M | $259.04M |
| 1-day change | +2.04% | +5.18% |
| YTD return | — | +95.56% |
| 1-year return | — | +45.86% |
| 5-year return | — | -96.48% |
| EPS (TTM) | $-2.04 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.80 | $6.95 |
| 52-week low | $7.88 | $1.21 |
| Distance from 52-week high | -49.44% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +268.44% | +177.65% |
| Average volume | 16.10K | 1.21M |
| Shares outstanding | 28.16M | 98.12M |
| Employees | 46 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
VCRE vs ZNTL FAQ
Which is bigger, Vicore Pharma AB or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $253.48M for Vicore Pharma AB (VCRE).
Are Vicore Pharma AB and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.